Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Inclusion Criteria:

- Histologic diagnosis of classical, CD30 positive Hodgkin lymphoma confirmed at
enrolling institution

- FDG-avid disease by FDG-PET/CT and measurable disease of at least 1.5 cm by CT

- Ann Arbor Stage I or II disease

- Disease bulk defined as any lymph node mass with transverse maximal diameter > 7.0 cm
OR coronal maximal diameter > 7.0 cm on CT imaging

- Females of childbearing age must be on an acceptable form of birth control per
institutional standards

- Ages 18 and over

Exclusion Criteria:

- Cardiac ejection fraction ≤ 50%

- Hemoglobin-adjusted diffusing capacity for carbon monoxide < 40%

- ANC≤1000/μl and Platelets≤75,000/μl

- Total bilirubin ≥ 2.0 mg/dl in the absence of a history of Gilbert's disease

- Serum creatinine clearance of <30 mL/min as estimated by the Cockcroft-Gault Method

- Known pregnancy or breast-feeding

- Known history of testing positive for human immunodeficiency virus (HIV) or known
acquired immunodeficiency syndrome (AIDS)

- Medical illness unrelated to Hodgkin Lymphoma, which, in the opinion of the attending
physician and/or MSKCC principal investigator, makes participation in this study
inappropriate.

- Peripheral neuropathy > grade 1

- Patients receiving chronic treatment with systemic steroids. However, patients can
receive up to 10 days of steroid therapy prior to starting treatment with BV+AVD.